UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and
Sale of Ordinary Shares and American Depositary Shares
This notification sets out the vesting details for Persons
Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus
Awards over Ordinary Shares and American Depositary Shares ('ADSs')
made in 2022 under the GlaxoSmithKline 2017 Deferred Annual Bonus
Plan ('DABP') and subsequent sale of Ordinary Shares and ADSs to
meet tax liabilities. In accordance with the shareholder
approved 2017 Remuneration Policy and the DABP rules, the awards
comprised a mandatory bonus deferral only. The three-year
restricted period for the awards commenced on 15 February 2022 and
ended on 17 February 2025 for Ordinary Shares and 18 February 2025
for ADSs. Dividends accrued on the awards during the restricted
period.
The awards were granted in 2022 as restricted awards over ADSs for
US participants and as nil-cost options over Ordinary Shares for
all other participants.
The closing price of Ordinary Shares of GSK plc on 17 February 2025
was £14.195 and the closing price of ADSs of GSK plc on 18
February 2025 was $36.61.
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Emma Walmsley
|
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The vesting of an award in the form of a nil-cost option over
Ordinary Shares granted in 2022 under the Company's 2017 Deferred
Annual Bonus Plan and the subsequent exercise of the nil-cost
option
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£0.00
|
81,703
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Emma Walmsley
|
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the exercise
of a nil-cost option award granted in 2022 under the Company's 2017
Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.1818
|
38,459
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Dr Hal Barron
|
|
|
b)
|
Position/status
|
Non-Executive Director
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
|
b)
|
Nature
of the transaction
|
The vesting of an award granted in 2022 under the Company's 2017
Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$0.00
|
45,690
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-18
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Dr Hal Barron
|
|
|
b)
|
Position/status
|
Non-Executive Director
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
|
b)
|
Nature
of the transaction
|
The sale of ADSs' to meet tax liabilities on the vesting of an
award granted in 2022 under the Company's 2017 Deferred Annual
Bonus Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$36.6355
|
24,623
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-18
|
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Diana Conrad
|
|
|
b)
|
Position/status
|
Chief People Officer
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The vesting of an award in the form of a nil-cost option over
Ordinary Shares granted in 2022 under the Company's 2017 Deferred
Annual Bonus Plan and the subsequent exercise of the nil-cost
option
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£0.00
|
12,825
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Diana Conrad
|
|
|
b)
|
Position/status
|
Chief People Officer
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the exercise
of a nil-cost option award granted in 2022 under the Company's 2017
Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2070
|
6,883
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
James Ford
|
|
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The vesting of an award in the form of a nil-cost option over
Ordinary Shares granted in 2022 under the Company's 2017 Deferred
Annual Bonus Plan and the subsequent exercise of the nil-cost
option
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£0.00
|
15,792
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
James Ford
|
|
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the exercise
of a nil-cost option award granted in 2022 under the Company's 2017
Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2001
|
7,441
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Sally Jackson
|
|
|
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The vesting of an award in the form of a nil-cost option over
Ordinary Shares granted in 2022 under the Company's 2017 Deferred
Annual Bonus Plan and the subsequent exercise of the nil-cost
option
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£0.00
|
7,371
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Sally Jackson
|
|
|
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the exercise
of a nil-cost option award granted in 2022 under the Company's 2017
Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2000
|
3,477
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Luke Miels
|
|
|
b)
|
Position/status
|
Chief Commercial Officer
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The vesting of an award in the form of a nil-cost option over
Ordinary Shares granted in 2022 under the Company's 2017 Deferred
Annual Bonus Plan and the subsequent exercise of the nil-cost
option
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£0.00
|
26,851
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Luke Miels
|
|
|
b)
|
Position/status
|
Chief Commercial Officer
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the exercise
of a nil-cost option award granted in 2022 under the Company's 2017
Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.1950
|
618
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Shobie Ramakrishnan
|
|
|
b)
|
Position/status
|
Chief Digital and Technology Officer
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
|
b)
|
Nature
of the transaction
|
The vesting of an award granted in 2022 under the Company's 2017
Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$0.00
|
2,786
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-18
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Shobie Ramakrishnan
|
|
|
b)
|
Position/status
|
Chief Digital and Technology Officer
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
|
b)
|
Nature
of the transaction
|
The sale of ADSs' to meet tax liabilities on the vesting of an
award granted in 2022 under the Company's 2017 Deferred Annual
Bonus Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$36.6355
|
1,502
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-18
|
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
David Redfern
|
|
|
b)
|
Position/status
|
President Corporate Development
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The vesting of an award in the form of a nil-cost option over
Ordinary Shares granted in 2022 under the Company's 2017 Deferred
Annual Bonus Plan and the subsequent exercise of the nil-cost
option
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£0.00
|
17,805
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
David Redfern
|
|
|
b)
|
Position/status
|
President Corporate Development
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the exercise
of a nil-cost option award granted in 2022 under the Company's 2017
Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.1906
|
8,390
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Regis Simard
|
|
|
b)
|
Position/status
|
President, Global Supply Chain
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The vesting of an award in the form of a nil-cost option over
Ordinary Shares granted in 2022 under the Company's 2017 Deferred
Annual Bonus Plan and the subsequent exercise of the nil-cost
option
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£0.00
|
16,172
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Regis Simard
|
|
|
b)
|
Position/status
|
President, Global Supply Chain
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the exercise
of a nil-cost option award granted in 2022 under the Company's 2017
Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.1954
|
7,620
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2054-02-17
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Phil Thomson
|
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The vesting of an award in the form of a nil-cost option over
Ordinary Shares granted in 2022 under the Company's 2017 Deferred
Annual Bonus Plan and the subsequent exercise of the nil-cost
option
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£0.00
|
11,220
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Phil Thomson
|
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the exercise
of a nil-cost option award granted in 2022 under the Company's 2017
Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.1929
|
5,287
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Deborah Waterhouse
|
|
|
b)
|
Position/status
|
CEO, ViiV Healthcare and President, Global Health, GSK
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The vesting of an award in the form of a nil-cost option over
Ordinary Shares granted in 2022 under the Company's 2017 Deferred
Annual Bonus Plan and the subsequent exercise of the nil-cost
option
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£0.00
|
11,841
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Deborah Waterhouse
|
|
|
b)
|
Position/status
|
CEO, ViiV Healthcare and President, Global Health, GSK
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the exercise
of a nil-cost option award granted in 2022 under the Company's 2017
Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.1985
|
5,580
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2025-02-17
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
20, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|